|
|
|
Insider
Information: |
Harshbarger Benjamin |
Relationship: |
See Remarks |
City: |
Cambridge |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
3,683 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$2,585 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
3,683 |
|
|
Total
Value |
$2,585 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Aegerion Pharmaceuticals, Inc. |
AEGR |
General Counsel and Se... |
2016-11-29 |
0 |
2016-04-01 |
0 |
Premium* |
|
Novelion Therapeutics Inc |
NVLN |
See Remarks |
2019-05-09 |
3,683 |
2016-11-29 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
19 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
AEGR |
Aegerion Pharmaceuticals,... |
General Counsel and Secretary |
|
2016-11-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,704) |
0 |
0 |
- |
|
NVLN |
Novelion Therapeutics Inc |
General Counsel |
|
2017-04-01 |
4 |
D |
$10.74 |
$612 |
D/D |
(57) |
470 |
0 |
- |
|
NVLN |
Novelion Therapeutics Inc |
General Counsel |
|
2017-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
178 |
527 |
0 |
- |
|
AEGR |
Aegerion Pharmaceuticals,... |
General Counsel |
|
2016-04-01 |
4 |
D |
$3.55 |
$969 |
D/D |
(273) |
594 |
0 |
- |
|
AEGR |
Aegerion Pharmaceuticals,... |
General Counsel |
|
2016-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
867 |
867 |
0 |
- |
|
NVLN |
Novelion Therapeutics Inc |
General Counsel |
|
2017-05-09 |
4 |
D |
$9.42 |
$2,204 |
D/D |
(234) |
960 |
0 |
- |
|
NVLN |
Novelion Therapeutics Inc |
General Counsel |
|
2017-05-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
724 |
1,081 |
0 |
- |
|
NVLN |
Novelion Therapeutics Inc |
General Counsel |
|
2017-05-15 |
4 |
D |
$8.97 |
$2,081 |
D/D |
(232) |
1,445 |
0 |
- |
|
NVLN |
Novelion Therapeutics Inc |
General Counsel |
|
2017-09-17 |
4 |
D |
$7.08 |
$772 |
D/D |
(109) |
1,673 |
0 |
- |
|
NVLN |
Novelion Therapeutics Inc |
General Counsel |
|
2017-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
717 |
1,677 |
0 |
- |
|
AEGR |
Aegerion Pharmaceuticals,... |
General Counsel |
|
2016-09-17 |
4 |
D |
$1.78 |
$947 |
D/D |
(532) |
1,704 |
0 |
- |
|
NVLN |
Novelion Therapeutics Inc |
General Counsel and Secretary |
|
2016-11-29 |
4 |
A |
$0.00 |
$0 |
D/D |
1,747 |
1,747 |
0 |
- |
|
NVLN |
Novelion Therapeutics Inc |
General Counsel |
|
2017-09-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
337 |
1,782 |
0 |
- |
|
AEGR |
Aegerion Pharmaceuticals,... |
General Counsel |
|
2016-09-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,642 |
2,236 |
0 |
- |
|
NVLN |
Novelion Therapeutics Inc |
See Remarks |
|
2019-05-09 |
4 |
D |
$1.22 |
$259 |
D/D |
(212) |
3,683 |
0 |
- |
|
NVLN |
Novelion Therapeutics Inc |
General Counsel |
|
2018-09-17 |
4 |
D |
$3.94 |
$386 |
D/D |
(98) |
3,895 |
0 |
- |
|
NVLN |
Novelion Therapeutics Inc |
General Counsel |
|
2018-05-15 |
4 |
D |
$4.15 |
$623 |
D/D |
(150) |
3,993 |
0 |
- |
|
NVLN |
Novelion Therapeutics Inc |
General Counsel |
|
2018-05-09 |
4 |
D |
$4.26 |
$1,372 |
D/D |
(322) |
4,143 |
0 |
- |
|
NVLN |
Novelion Therapeutics Inc |
General Counsel |
|
2018-04-01 |
4 |
D |
$3.50 |
$182 |
D/D |
(52) |
4,465 |
0 |
- |
|
19 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|